Actuate Therapeutics, Inc.
ACTU
$6.45
-$0.33-4.87%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 196.76% | 156.11% | 98.57% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.04% | -13.46% | 0.75% | -- | -- |
| Operating Income | 11.04% | 13.46% | -0.75% | -- | -- |
| Income Before Tax | 14.35% | 8.87% | -10.27% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.35% | 8.87% | -10.27% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.35% | 8.87% | -10.27% | -- | -- |
| EBIT | 11.04% | 13.46% | -0.75% | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 92.04% | 71.03% | 38.99% | -- | -- |
| Normalized Basic EPS | 92.07% | 74.08% | 44.69% | -- | -- |
| EPS Diluted | 92.04% | 71.03% | 38.99% | -- | -- |
| Normalized Diluted EPS | 92.07% | 74.08% | 44.69% | -- | -- |
| Average Basic Shares Outstanding | 1,043.18% | 766.10% | 482.54% | -- | -- |
| Average Diluted Shares Outstanding | 1,043.18% | 766.10% | 482.54% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |